The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments

[1]  F. Merli,et al.  A GENE EXPRESSION‐BASED SCORE TO PREDICT INTERIM PET POSITIVITY IN HODGKIN LYMPHOMA PATIENTS TREATED WITH ABVD , 2019, Hematological Oncology.

[2]  Martin Hutchings,et al.  Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. , 2018, Blood.

[3]  C. Vetro,et al.  Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy , 2018, Annals of Hematology.

[4]  A. Rossi,et al.  Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Burton,et al.  CAN BASELINE PET‐CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033) , 2017 .

[6]  P. Gobbi,et al.  Neutrophil‐lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients , 2016, Hematological oncology.

[7]  R. Gascoyne,et al.  The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. , 2016, The Lancet. Haematology.

[8]  A. Levis,et al.  Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Gascoyne,et al.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. d'Amore,et al.  Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. , 2016, The New England journal of medicine.

[11]  R. Advani,et al.  Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era , 2015, British journal of haematology.

[12]  P. Gobbi,et al.  Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. , 2015, Mayo Clinic proceedings.

[13]  Alexandre Cochet,et al.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  R. Advani,et al.  Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Advani,et al.  Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Gascoyne,et al.  International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Steven J. M. Jones,et al.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[18]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.